KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) EBIT (2016 - 2025)

Regeneron Pharmaceuticals has reported EBIT over the past 17 years, most recently at $879.9 million for Q4 2025.

  • Quarterly results put EBIT at $879.9 million for Q4 2025, down 11.14% from a year ago — trailing twelve months through Dec 2025 was $3.6 billion (down 10.34% YoY), and the annual figure for FY2025 was $3.6 billion, down 10.34%.
  • EBIT for Q4 2025 was $879.9 million at Regeneron Pharmaceuticals, down from $1.0 billion in the prior quarter.
  • Over the last five years, EBIT for REGN hit a ceiling of $3.3 billion in Q2 2021 and a floor of $591.7 million in Q1 2025.
  • Median EBIT over the past 5 years was $1.1 billion (2022), compared with a mean of $1.3 billion.
  • Biggest five-year swings in EBIT: skyrocketed 409.93% in 2021 and later tumbled 66.84% in 2022.
  • Regeneron Pharmaceuticals' EBIT stood at $2.6 billion in 2021, then crashed by 56.56% to $1.1 billion in 2022, then decreased by 15.16% to $972.9 million in 2023, then grew by 1.78% to $990.2 million in 2024, then dropped by 11.14% to $879.9 million in 2025.
  • The last three reported values for EBIT were $879.9 million (Q4 2025), $1.0 billion (Q3 2025), and $1.1 billion (Q2 2025) per Business Quant data.